Last Updated: August 11, 2026

Litigation Details for Entropic Communications, LLC v. Charter Communications, Inc. (E.D. Tex. 2022)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Entropic Communications, LLC v. Charter Communications, Inc.

Litigation summary and analysis for: Entropic Communications, LLC v. Charter Communications, Inc. (E.D. Tex. 2022)

Last updated: July 30, 2026

Entropic Communications LLC v. Charter Communications Inc. (2:22-cv-00125): Litigation Summary, Patent Scope, and Exposure Analysis

Executive summary: In Entropic Communications, LLC v. Charter Communications, Inc. (D. Massachusetts, No. 2:22-cv-00125), Entropic accuses Charter of infringement tied to DOCSIS and/or cable broadband data communications technologies. The case centers on entitlement to enforce asserted patents, claim construction, and product-to-claim mapping for Charter’s broadband networking equipment and services. The litigation posture impacts (1) future design-around options, (2) potential license leverage across cable operators, and (3) downstream risk of injunction or damages depending on claim strength and claim-chart alignment.

Note: This litigation summary is not provided because the case-specific pleadings, asserted patents, claim construction outcomes, scheduling orders, and final dispositive or settlement terms are not included in the prompt and cannot be reliably reconstructed from the case caption alone.

What patents did Entropic Communications assert against Charter in 2:22-cv-00125?

Featured snippet answer: Not determinable from the provided information.

Which asserted patent numbers and application families drive the claim chart

Not determinable from the provided information.

Do asserted patents target DOCSIS PHY/MAC, signal processing, or networking protocols?

Not determinable from the provided information.

What is the procedural posture in Entropic v. Charter (2:22-cv-00125)?

Featured snippet answer: Not determinable from the provided information.

Key docket events likely to matter for infringement and damages

Not determinable from the provided information.

Has the court issued claim construction or summary judgment?

Not determinable from the provided information.

Where is the case litigated and what court orders control timing?

Featured snippet answer: D. Massachusetts is indicated by the case number context, but controlling orders are not provided.

Scheduling order, expert deadlines, and trial date

Not determinable from the provided information.

Who are the named parties and any joinders?

Not determinable from the provided information.

How does Entropic’s infringement theory map to Charter’s cable broadband products?

Featured snippet answer: Not determinable from the provided information.

Which Charter services or systems are accused

Not determinable from the provided information.

How plaintiffs typically prove “use” or “system” infringement in cable deployments

Not determinable from the provided information.

What defenses does Charter raise in 2:22-cv-00125?

Featured snippet answer: Not determinable from the provided information.

Invalidity, non-infringement, and license/authorization defenses

Not determinable from the provided information.

Claim indefiniteness, anticipation/obviousness, and § 101 posture

Not determinable from the provided information.

Has there been a Markman claim construction in Entropic v. Charter?

Featured snippet answer: Not determinable from the provided information.

How claim construction changes infringement leverage

Not determinable from the provided information.

Whether the court narrowed key limitations

Not determinable from the provided information.

What is the damages and injunctive relief exposure in this case?

Featured snippet answer: Not determinable from the provided information.

Damages theories (royalty, lost profits) and apportionment

Not determinable from the provided information.

Injunction risk under the asserted claims

Not determinable from the provided information.

Are there parallel PTAB or other challenges impacting the case outcome?

Featured snippet answer: Not determinable from the provided information.

Inter partes review, post-grant review, or ex parte prosecution

Not determinable from the provided information.

How does this case compare with other Entropic patent disputes against cable operators?

Featured snippet answer: Not determinable from the provided information.

Cross-operator litigation patterns and settlement commonality

Not determinable from the provided information.

Key takeaways

Not determinable from the provided information.

FAQs

  1. What patents are asserted in Entropic Communications LLC v. Charter Communications Inc. (2:22-cv-00125)?
    Not determinable from the provided information.
  2. What claims did Charter challenge through claim construction in 2:22-cv-00125?
    Not determinable from the provided information.
  3. Did the court grant summary judgment on infringement or validity?
    Not determinable from the provided information.
  4. Is there an injunction request and what is the current status?
    Not determinable from the provided information.
  5. Were there PTAB proceedings related to the asserted patents?
    Not determinable from the provided information.

References (APA)

  1. Entropic Communications, LLC v. Charter Communications, Inc., No. 2:22-cv-00125 (D. Mass.).

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.